Retatrutide Benefits: What Studies Report

Retatrutide (LY3437943) is an investigational medicine that is being evaluated in clinical trials and has not received marketing approval from the US Food and Drug Administration, the European Medicines Agency or other major regulators for any indication. Because there is no approved label, there are no approved indications and no label level outcomes to describe. What follows is a summary of endpoints that published trials and peer reviewed reviews measured and reported, organised by outcome domain, with the study type and population stated in each case. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, any condition and any question about suitability.

What the published literature describes retatrutide as

Published reviews describe retatrutide as a single peptide designed to act as an agonist at three receptors, the glucose dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (PMID 40563436). A 2026 phase 3 report in the Lancet similarly identified retatrutide as a GIP, GLP-1 and glucagon receptor agonist studied in people with type 2 diabetes (PMID 42250575). Broader pipeline reviews placed retatrutide among multi-agonist candidates in late stage development for obesity alongside other incretin based agents (PMID 38302593), and a systematic review of emerging obesity pharmacotherapies catalogued these agents and their reported trial results (PMID 39952695).

How the word "benefits" is handled here

For an approved medicine, benefits are the outcomes listed on a regulator approved label. Retatrutide has no such label, so the only defensible framing is the one used throughout this page: what researchers measured, in whom, over what period, and what direction of effect the study reported. A finding in a phase 2 trial is a measured endpoint in a defined population, not a general claim about what a medicine does. Review articles have argued that the obesity treatment field still needs agents with greater efficacy and better tolerability, which is the context in which these trials were designed (PMID 39726721).

Body weight: what studies report

The most cited human dataset is a phase 2 randomised, double blind, placebo controlled trial published in the New England Journal of Medicine in 2023, which enrolled adults with obesity, or with overweight plus at least one weight related condition, and compared weekly subcutaneous retatrutide across dose groups ranging from 1 mg to 12 mg with placebo over 48 weeks (PMID 37366315). The study reported dose related reductions in mean body weight, with a change of approximately 24 percent from baseline at 48 weeks in the highest dose group compared with approximately 2 percent in the placebo group (PMID 37366315). Researchers also reported dose related weight change at the 24 week interim timepoint, with the trial continuing to 48 weeks (PMID 37366315).

Secondary literature has summarised that phase 2 result within the wider incretin field. A 2025 review characterised retatrutide as a prominent candidate in obesity pharmacotherapy and reviewed the phase 2 weight outcomes alongside its mechanism (PMID 40563436), and a systematic review of emerging obesity drugs placed those findings among other investigational agents still awaiting registrational data (PMID 39952695). For context on the approved incretin class rather than retatrutide itself, a systematic review of randomised controlled trials of GLP-1 receptor agonists in adults without diabetes reported weight reduction relative to placebo across the trials analysed (PMID 39761578).

What the weight data do not establish

A phase 2 trial measures a surrogate endpoint over a defined period in a selected population. It does not establish long term outcomes such as cardiovascular events, mortality or durability of weight change after treatment ends, and the cited phase 2 report did not address those questions (PMID 37366315). Registrational programmes are described as ongoing in the design literature (PMID 41090431).

Glycaemic outcomes: what studies report

A phase 3 trial known as TRANSCEND-T2D-1, published in the Lancet, was a double blind, randomised study of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise, and it reported on efficacy and safety in that population (PMID 42250575). Reviews of newer type 2 diabetes drug therapies have discussed multi-receptor agonists within the evolving treatment landscape (PMID 38183334), and a Diabetes Care review of GLP-1 medicines examined efficacy and safety for type 2 diabetes and obesity at a class level rather than for any single investigational agent (PMID 38843460). Whether any of this applies to an individual person with diabetes is a question for a prescribing clinician, not for a summary page.

Body composition: what studies report

Body composition is frequently searched for and is only indirectly addressed in the verified literature. A Diabetes Care perspective on incretin based weight loss pharmacotherapy discussed the observation that substantial weight reduction includes loss of fat free mass as well as fat mass, and examined whether resistance exercise could influence the composition of that change (PMID 38687506). That article was a review of the incretin class and the role of exercise, not a retatrutide specific body composition trial, so it should not be read as a retatrutide finding (PMID 38687506).

Outcomes currently under investigation

A 2026 design paper in Diabetes, Obesity and Metabolism set out the rationale and design of the TRIUMPH registrational clinical trial programme, which is studying retatrutide in obesity, obstructive sleep apnoea and knee osteoarthritis (PMID 41090431). A design and rationale publication describes planned populations, endpoints and procedures; it does not report efficacy results, and the cited paper accordingly provides no outcome data for those three conditions (PMID 41090431). These are investigational research questions rather than established uses.

Preclinical work

One 2025 preclinical report, conducted in laboratory models rather than in people, described retatrutide (LY3437943) as alleviating obesity associated cancer progression in that experimental setting (PMID 40094000). Animal and laboratory findings do not translate reliably to humans, and the cited work was not a clinical trial in patients (PMID 40094000).

Evidence summary by outcome domain

Adverse Events: What Studies Report

In the 48 week phase 2 obesity trial, the most commonly reported adverse events were gastrointestinal, were mostly mild to moderate in severity, occurred predominantly during dose escalation and were reported as partially mitigated by a lower starting dose (PMID 37366315). The phase 3 trial in type 2 diabetes reported safety alongside efficacy in that population (PMID 42250575). At a class level, a 2024 Diabetes Care review examined the efficacy and safety profile of GLP-1 medicines used for type 2 diabetes and obesity (PMID 38843460), and a systematic review of randomised trials in adults without diabetes reported gastrointestinal adverse events as the most frequent category with these agents (PMID 39761578). Safety interpretation for any individual belongs with a licensed physician who can review the full prescribing context.

Where the evidence is thin or absent

• Cardiovascular outcome data. None of the cited retatrutide publications reported completed cardiovascular outcome trial results; the phase 2 report addressed weight change over 48 weeks (PMID 37366315).
• Long term durability. The longest retatrutide treatment duration in the cited phase 2 publication was 48 weeks (PMID 37366315), and registrational trials were described as in progress (PMID 41090431).
• Head to head comparisons. The cited reviews summarised agents within a developing pipeline rather than reporting definitive direct comparisons (PMID 38302593, PMID 39952695).
• Athletic performance, cosmetic and longevity claims. No cited study in this set measured such outcomes, and reviews of the field focused on obesity and metabolic endpoints (PMID 39726721).

Reading trial reports carefully

1. Check the phase. Phase 2 results such as those reported in the 2023 obesity trial are hypothesis generating for later registrational work (PMID 37366315).
2. Check the population. The glycaemic trial enrolled adults with type 2 diabetes inadequately controlled with diet and exercise, a narrower group than the general population (PMID 42250575).
3. Separate design papers from results papers. The TRIUMPH publication described rationale and design and did not report outcomes (PMID 41090431).
4. Separate preclinical from clinical. Laboratory model findings remain preclinical until tested in people (PMID 40094000).

Regulatory status is the single most important framing point on this topic: retatrutide remains investigational, its evidence base is still accumulating through registrational trials (PMID 41090431), and decisions about treatment of obesity or type 2 diabetes are made by a licensed prescribing clinician using approved therapies and an individual medical history.

References

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (The New England Journal of Medicine, 2023)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1) (Lancet, 2026)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Retatrutide: A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression (npj Metabolic Health and Disease, 2025)
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (Diabetes Care, 2024)
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials (Annals of Internal Medicine, 2025)
• Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (Diabetes Care, 2024)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• What is the pipeline for future medications for obesity? (International Journal of Obesity, 2025)
• Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies (The Kaohsiung Journal of Medical Sciences, 2024)
• Why are we still in need for novel anti-obesity medications? (The Lancet Regional Health Europe, 2024)